BlackRock’s Nektar Therapeutics NKTR Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$49.8M Buy
692,650
+47,043
+7% +$2.68M ﹤0.01% 2501
2025
Q4
$27.3M Buy
645,607
+36,493
+6% +$2.04M ﹤0.01% 2912
2025
Q3
$34.7M Buy
609,114
+193,888
+47% +$6.42M ﹤0.01% 2739
2025
Q2
$10.7M Sell
415,226
-631,929
-60% -$7.1M ﹤0.01% 3378
2025
Q1
$10.7M Sell
1,047,155
-25,617
-2% -$335K ﹤0.01% 3281
2024
Q4
$15M Buy
1,072,772
+8,149
+0.8% +$144K ﹤0.01% 3213
2024
Q3
$20.8M Buy
1,064,623
+54,245
+5% +$1.03M ﹤0.01% 3017
2024
Q2
$18.8M Buy
1,010,378
+618,492
+158% +$13M ﹤0.01% 3026
2024
Q1
$5.49M Sell
391,886
-15,062
-4% -$158K ﹤0.01% 3631
2023
Q4
$3.45M Sell
406,948
-105,361
-21% -$798K ﹤0.01% 3843
2023
Q3
$4.58M Sell
512,309
-61,312
-11% -$590K ﹤0.01% 3690
2023
Q2
$4.95M Sell
573,621
-1,796,976
-76% -$19.2M ﹤0.01% 3734
2023
Q1
$25M Sell
2,370,597
-24,784
-1% -$750K ﹤0.01% 2857
2022
Q4
$81.2M Buy
2,395,381
+58,680
+3% +$2.84M ﹤0.01% 2144
2022
Q3
$112M Buy
2,336,701
+231,840
+11% +$13.8M ﹤0.01% 1890
2022
Q2
$120M Buy
2,104,861
+363,893
+21% +$23M ﹤0.01% 1904
2022
Q1
$141M Sell
1,740,968
-37,152
-2% -$5.5M ﹤0.01% 1908
2021
Q4
$360M Buy
1,778,120
+521,837
+42% +$113M 0.01% 1279
2021
Q3
$338M Buy
1,256,283
+16,532
+1% +$3.98M 0.01% 1307
2021
Q2
$319M Sell
1,239,751
-28,725
-2% -$7.95M 0.01% 1424
2021
Q1
$381M Buy
1,268,476
+43,271
+4% +$13.5M 0.01% 1251
2020
Q4
$312M Buy
1,225,205
+26,793
+2% +$6.92M 0.01% 1267
2020
Q3
$298M Sell
1,198,412
-47,130
-4% -$14.8M 0.01% 1080
2020
Q2
$433M Buy
1,245,542
+40,933
+3% +$12.8M 0.02% 811
2020
Q1
$323M Sell
1,204,609
-23,227
-2% -$7.18M 0.02% 853
2019
Q4
$398M Buy
1,227,836
+323,951
+36% +$93.9M 0.02% 972
2019
Q3
$247M Buy
903,885
+19,553
+2% +$7.17M 0.01% 1250
2019
Q2
$472M Buy
884,332
+49,976
+6% +$25.1M 0.02% 780
2019
Q1
$421M Sell
834,356
-30,923
-4% -$18.3M 0.02% 850
2018
Q4
$427M Sell
865,279
-9,505
-1% -$5.74M 0.02% 743
2018
Q3
$800M Buy
874,784
+30,877
+4% +$26.4M 0.03% 505
2018
Q2
$618M Sell
843,907
-120,827
-13% -$139M 0.03% 602
2018
Q1
$1.54B Sell
964,734
-464,025
-32% -$598M 0.07% 269
2017
Q4
$1.28B Buy
1,428,759
+28,751
+2% +$17M 0.06% 316
2017
Q3
$504M Buy
1,400,008
+51,909
+4% +$16.2M 0.03% 662
2017
Q2
$395M Buy
1,348,099
+12,396
+0.9% +$3.58M 0.02% 783
2017
Q1
$470M Buy
1,335,703
+1,334,963
+180,400% +$300M 0.03% 683
2016
Q4
$136K Sell
740
-119
-14% -$24.2K ﹤0.01% 2373
2016
Q3
$221K Buy
859
+80
+10% +$20.6K ﹤0.01% 2094
2016
Q2
$166K Buy
779
+178
+30% +$39.8K ﹤0.01% 2211
2016
Q1
$124K Buy
601
+257
+75% +$49.4K ﹤0.01% 1904
2015
Q4
$87K Buy
344
+145
+73% +$29.8K ﹤0.01% 1817
2015
Q3
$33K Sell
199
-31
-13% -$5.48K ﹤0.01% 2110
2015
Q2
$43K Sell
230
-15
-6% -$2.58K ﹤0.01% 2036
2015
Q1
$40K Hold
245
﹤0.01% 2044
2014
Q4
$57K Hold
245
﹤0.01% 1891
2014
Q3
$45K Hold
245
﹤0.01% 1955
2014
Q2
$47K Sell
245
-7
-3% -$1.24K ﹤0.01% 1952
2014
Q1
$46K Buy
252
+11
+5% +$2.18K ﹤0.01% 1953
2013
Q4
$41K Sell
241
-8
-3% -$1.29K ﹤0.01% 2004
2013
Q3
$39K Buy
249
+9
+4% +$1.66K ﹤0.01% 1943
2013
Q2
$41K Buy
+240
New +$36.8K ﹤0.01% 1939

Other funds holding NKTR

BlackRock's NKTR Position: Q1 2026 in Review

BlackRock increased its Nektar Therapeutics (NKTR) stake by 7.3% in Q1 2026, buying an estimated $2.68M and bringing the position to 692,650 shares worth $49.8M. The position accounts for ﹤0.01% of the portfolio, ranked #2501.

BlackRock first reported a position in NKTR in Q2 2013 and has held it in 52 quarters since. The position peaked at $1.54B in Q1 2018. 215 funds tracked by Wall St. Rank hold NKTR as of Q1 2026.

  • BlackRock held 692,650 shares of Nektar Therapeutics worth $49.8M as of Q1 2026.
  • BlackRock bought 47,043 Nektar Therapeutics shares in Q1 2026, an estimated $2.68M.
  • Nektar Therapeutics made up ﹤0.01% of BlackRock's portfolio in Q1 2026, its #2501 holding.
  • BlackRock first reported a position in Nektar Therapeutics in Q2 2013 and has held it in 52 quarters since.
  • BlackRock's Nektar Therapeutics position peaked at $1.54B in Q1 2018.
  • 215 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q1 2026.

Based on BlackRock's 13F filing for Q1 2026, filed 13 May 2026.